6-Hydroxysandoricin

Metabolite details

Identifier

NKHYHRMLCJNKHW-UHFFFAOYSA-N

InChI Key

NKHYHRMLCJNKHW-UHFFFAOYSA-N

IUPAC name

methyl 2-[5,11-diacetyloxy-13-(uran-3-yl)-16-hydroxy-6,6,8,12-tetramethyl-17-methylidene-15-oxo-2,14-dioxatetracyclo[7.7.1.01,12.03,8]heptadecan-7-yl]-2-hydroxyacetate

Preferred name

6-Hydroxysandoricin

INN name

—

Synonym

—

ChEBI

CHEBI:185400

Reactome pathways

• No Reactome pathways listed for this metabolite.

Observed in studies

• Bioaccumulation of therapeutic drugs by human gut bacteria: cross-feeding metabolite analysis (FIA-MS) (E.rectale;S.salivarius assays)
• Multi-Omics Analysis Reveals Disturbance of Nanosecond Pulsed Electric Field in the Serum Metabolic Spectrum and Gut Microbiota
• Diallyl disulfide (DADS) ameliorates intestinal Candida albicans infection by modulating the gut microbiota and metabolites and providing intestinal protection in mice
• Effects of Radiofrequency Field from 5G Communications on fecal microbiome and metabolome profiles in mice
• Alterations in the gut microbiota and metabolomics of seafarers after a six-month sea voyage

Observed in differential profiles

• G4_Eubacterium_rectale_DMSO_30_vs_G3_Eubacterium_rectale_Duloxetine_47
• Control_vs_nsPEF_7_day
• G1_PBS_vs_G2_DSS
• Sham_vs_Radiofrequency
• Control_0d_vs_Treatment_180d
• Control_0d_vs_Treatment_180d